could close valuat gap growth rebound
neutral rate follow acquisit cynosur cyno februari
base thesi profit would suffer uncomfort
recommend share given unfamiliar medic aesthet space
appear rush deal caution cyno seem warrant
still risk cyno comp get easier rest
expect stock reward cyno rebound manag expect howev
upgrad buy due fact core busi solid
upsid potenti tailwind tax reform valuat attract
see multipl trend back toward level sum-of-the-part analysi
suggest core busi worth suggest us current
valuat exclud benefit cynosur and/or tax reform
still reserv cyno think expect bottom
interest product-specif growth driver also rel
beneficiari tax reform given us exposur sale higher tax rate
lower corpor rate boost ep beyond
layer benefit tax assum cyno grow
believ cyno free call option continu
believ holx core busi expand ou deliv innov
drive price power custom sticki pama protect access medicar act
overhang industri see gradual headwind share
trough updat est trade pe line
 median discount dx peer discount vs
histor trade discount peer cyno rebound plu tax
reform may help close gap
rais estim increas po
rais ep est take
tax rate respect year po base
ep previous use impli ev/ebitda believ
conserv still deep discount dx/medtech pariti could anoth
upsid beyond po
net dbt
still cautiou cyno tailwind hard
ignor upgrad buy po
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
lead manufactur medic
devic product focus heathcar need
mammographi breast biopsi earli stage
treatment remov uterin fibroid
compani acquir cynosur lead
medic aesthet compani larg portfolio
laser-bas product
core mammographi
diagnost busi perform better
expect especi ou market help
off-set concern surpris cynosur
acquisit done hide slow growth
continu reserv
cynosur believ expect like
bottom point call
option view better expect result
cynosur could help close valuat gap
dx peer
cr chart trade pe line
median discount dx peer discount
versu med-tech peer histor trade
discount dx med-tech peer
chart trade ebitda in-lin
year median dx peer discount med-tech peer
histor trade margin discount dx
sum-of-the-part analysi suggest core busi worth
roughli line current stock price market close
po base approxim calendar ep estim impli
ev/ebitda slightli three-year histor averag
upsid risk po better-than-expect synergi cynosur
acquisit unreal benefit chang tax code faster growth
core diagnost mammographi gynecolog surgeri end market
downsid risk po competit pressur slower uptak reimburs
new product unfavor chang clinic practic guidelin manag
departur regulatori risk faster declin legaci busi
derik de bruin herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
becton dickinson compani
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
